Reversal Mechanism of Multidrug Resistance by Verapamil: Direct Binding of Verapamil to P-Glycoprotein on Specific Sites and Transport of Verapamil Outward across the Plasma Membrane of K562/ADM Cells

Cancer Research

Volumn 49, Issue 18, 1989, Pages 5002-5006

  Yusa, Keisuke ^a   Tsuruo, Takashi ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; DILTIAZEM; DOXORUBICIN; GLYCOPROTEIN P; NICARDIPINE; RADIOISOTOPE; VERAPAMIL; VERAPAMIL DERIVATIVE; VINCRISTINE;

CELL CULTURE; CELL MEMBRANE; DRUG RESISTANCE; HUMAN; HUMAN CELL; LEUKEMIA CELL; PREVENTION; PRIORITY JOURNAL;

BIOLOGICAL TRANSPORT; BLOOD PROTEINS; CELL LINE; CELL MEMBRANE; DRUG RESISTANCE; HUMAN; KINETICS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MOLECULAR WEIGHT; P-GLYCOPROTEIN; PROTEIN BINDING; SUPPORT, NON-U.S. GOV'T; VERAPAMIL;

EID: 0024421664     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Skovsgaard, T. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res., 38:4722–4727, 1978.
2. Inaba, M., Kobayashi, H., Sakurai, Y., and Johnson, R. K. Active efflux of daunorubicin and Adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res., 39: 2200–2203,1979.
3. Juliano, R. L., and Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455: 152–162, 1976.
4. Beck, W. T., Mueller, T. J., and Tanzer, L. R. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res., 39: 2070–2076, 1979.
5. Debenham, P. G., Kartner, N., Siminovitch, L., Riordan, J. R., and Ling, V. DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Mol. Cell. Biol., 2:881–889, 1982.
6. Kartner, N., Riordan, J. R., and Ling, V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science (Wash. DC), 221:1285–1288, 1983.
7. Kartner, N., Evernden-Porelle, D., Bradley, G, and Ling, V. Detection of P-glycoprotein in multidrug-resistant cell line by monoclonal antibodies. Nature (Lond.), 316:820–823,1985.
8. Tsuruo, T., Iida-Saito, H., Kawabata, H., Oh-hara, T., Hamada, H., and Utakoji, T. Characteristics of resistance to Adriamycin in human myelogenous leukemia K562 resistant to Adriamycin and the isolated clones. Jpn. J. Cancer Res., 77:682–692, 1986.
9. Shen, D.-W., Fojo, A., Chin, J. E., Roninson, I. B., Richert, N., Pastan, I., and Gottesman, M. M. Science (Wash. DC), 232:643–645, 1986.
10. Gros, P., Neriah, Y. B., Croop, J. M., and Housman, D. E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature (Lond.), 323:728–731, 1986.
11. Ueda, K., Cardarelli, C., Gottesman, M. M., and Pastan, I. Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA, 84: 3004–3008, 1987.
12. Safa, A. R., Glover, C. J., Meyers, M. B., Bielder, J. L., and Felsted, R. L. Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J. Biol. Chem., 261: 6137–6139, 1986.
13. Cornwell, M. M., Safa, A. R., Felsted, R. L., Gottesman, M. M., and Pastan, I. Membrane vesicles from multidrug-resistant cancer cells contain a 150- to 170-kDa protein detected by photoaffinity labeling. Proc. Natl. Acad. Sci. USA, 83:3847–3850, 1986.
14. Hamada, H., and Tsuruo, T. Purification of the P-glycoprotein associated with multidrug resistance. J. Biol. Chem., 263:1454–1458, 1988.
15. Naito, M., Hamada, H., and Tsuruo, T. ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J. Biol. Chem., 263:11887–11891,1988.
16. Horio, M., Gottesman, M. M., and Pastan, I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc. Natl. Acad. Sci. USA, 85: 3580–3584, 1988.
17. Tsuruo, T., Lida, H., Tsukagoshi, S., and Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia, in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 41: 1967–1972, 1981.
18. Tsuruo, T., Iida, H., Tsukagoshi, S., and Sakurai, Y. Increased accumulation of vincristine and Adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res., 42:4730–4733,1982.
19. Tsuruo, T., Lida, H., Nojiri, M., Tsukagoshi, S., and Sakurai, Y. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res., 43: 2905–2910, 1983.
20. Slater, L. M., Murray, S. L., Wetzel, M. M., Wisdom, R. H., and Du Vail, E. M. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J. Clin. Invest., 10:1131–1134,1982.
21. Ramu, A., Fuks, Z., Gatt, S., and Glaubiger, D. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate. Cancer Res., 44:144–148, 1984.
22. Ganapathi, R., and Grabowski, D. Enhancement of sensitivity to Adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res., 43: 3696–3699,1983.
23. Rogan, A. M., Hamilton, T. C., Young, R. C., Klecker, R. W., and Ozols, R. F. Reversal of Adriamycin resistance by verapamil in human ovarian cancer. Science (Wash. DC), 224:994–996,1984.
24. Tsuruo, T. In: R. F. Ozols (ed.), Cancer Treatment and Research—Drug Resistance. The Hague: Martinus Nijhoff, in press, 1988.
25. Safa, A. R. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc. Natl. Acad. Sci. USA, 85:7187–7191, 1988.
26. Theodore, L. J., Nelson, W. L., Zobrist, R. H., Giacomini, K. M., and Giacomini, J. C. Studies on Ca2+ channel antagonists. 5-[(3,4-dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylpentyl isothiocyanate, a chemoaffinity ligand derived from verapamil. J. Med. Chem., 29: 1789–1792,1986.
27. Sugimoto, Y., Roninson, I. B., and Tsuruo, T. Decreased expression of the amplified mdr1 gene in revertants of multidrug-resistant human myelogenous leukemia K562 occurs without loss of amplified DNA. Mol. Cell. Biol., 7: 4549–4552, 1987.
28. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Geoke, N. M., Olson, B. J., and Klenk, D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem., 150: 76–85,1985.
29. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227:680–685,1970.
30. Hamada, H., and Tsuruo, T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. USA, 83: 7785–7789, 1986.
31. Sugimoto, Y., Nishimura, T., Suzuki, H., and Tanaka, N. Evidence of altered influx of Adriamycin into anthracycline-resistant cells. J. Antibiot. (Tokyo), 34:1064–1066, 1981.
32. Tsuruo, T., Matsuzaki, T., Matsushita, M., Saito, H., and Yokokura, T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21:71–74, 1988.
33. Broxterman, H. J., Pinedo, H. M., Kuiper, C. M., Kaptein, L. C. M., Schuurhuis, G. J., and Lankelma, J. Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells. FASEB J., 2:2278–2282,1988.
34. Kessel, D. Interactions among membrane transport systems: anthracyclines, calcium antagonists and anti-estrogens. Biochem. Pharmacol., 35: 2825– 2826, 1986.
35. Cano-Gauci, D. F., and Riordan, J. R. Action of calcium antagonists on multidrug resistant cells: specific cytotoxicity independent of increased cancer drug accumulation. Biochem. Pharmacol., 86: 2115–2123, 1987.
36. Safa, A. R., Glover, C. J., Meyers, M. B., Biedler, J. L., and Felsted, R. L. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J. Biol. Chem., 262: 7884–7888, 1987.